Navigation Links
Herbicides, Fibrate Drugs May Block Taste Receptors
Date:10/27/2009

More research needed to determine the health consequences of compounds in question, experts say

TUESDAY, Oct. 27 (HealthDay News) -- Some common herbicides and cholesterol drugs block a nutrient-sensing receptor known as T1R3, researchers report.

"Compounds that either activate or block T1R3 receptors could have significant metabolic effects, potentially influencing diseases such as obesity, type II diabetes and metabolic syndrome," study author Dr. Bedrich Mosinger said in a news release. Mosinger is a geneticist at the Monell Chemical Senses Center in Philadelphia.

The receptor helps the body detect sweetness and the savory taste known as umami. It's found on the tongue and also appears to be in the intestine and pancreas.

According to scientists, the receptors notice that nutrients are in food and set off their processing.

In the study, recently published online in the Journal of Medicinal Chemistry, researchers looked at two compounds -- fibrates and phenoxy-herbicides -- to see if they had an effect on the receptors.

Fibrate drugs treat disorders such as high cholesterol and triglycerides. Phenoxy-herbicides, including the commonplace 2,4-D, are used to combat destructive weeds.

The researchers, from Monell and Mount Sinai School of Medicine in New York City, found that both classes of compounds blocked the receptor from activating.

"The metabolic consequences of short- and long-term exposures of humans to phenoxy-herbicides are unknown," Mosinger said. "This is because most safety tests were done using animals, which have T1R3 receptors that are insensitive to these compounds."

Ultimately, he said, "given the number of compounds used in agriculture, medicine and the food industry that may affect human T1R3 and related receptors, more work is needed to identify the health-related effects of exposure to these compounds."

More information

Learn more about the sense of taste in this presentation for kids by the University of Washington.



-- Randy Dotinga



SOURCE: Monell Chemical Senses Center, news release, Oct. 9, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. (Multimedia Version): Abbott Receives FDA Approval for TRILIPIX(TM) (fenofibric acid), First and Only Fibrate Indicated for Use in Combination With a Statin for Cholesterol Management
2. Abbott Receives FDA Approval for TRILIPIX(TM) (fenofibric acid), First and Only Fibrate Indicated for Use in Combination With a Statin for Cholesterol Management
3. Drugs for Inflammatory Bowel Might Increase Cancer Risk
4. Drugs for Irritable Bowel Might Increase Cancer Risk
5. Pitt researchers find candidates for new HIV drugs
6. Designing drugs and their antidotes together improves patient care
7. Risk of abnormally slow heart rate twice as high in those taking drugs to slow Alzheimers
8. Teen attitudes toward smoking linked to likelihood of drinking and using drugs
9. UCLA study identifies 2 chemicals that could lead to new drugs for genetic disorders
10. GENova Biotherapeutics secures new cancer drugs targets
11. Reportlinker Adds World Anti-Obesity Drugs Market Report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... 12, 2017 , ... CitiDent and San Francisco dentists, Dr. ... Oventus O2Vent technology. As many as 18 million Americans are estimated to suffer ... Oral appliances can offer significant relief to about 75 percent of people with ...
(Date:10/12/2017)... , ... October 12, 2017 , ... IsoComforter, Inc. ( ... announced today the introduction of an innovative new design of the shoulder pad. ... you get maximum comfort while controlling your pain while using cold therapy. By utilizing ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... delivery system that we intend to develop to enable prevention of a major ... to severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss is ...
(Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts at Children’s ... the 49th Congress of the International Society of Paediatric Oncology (SIOP) Oct. ... Center for Cancer and Blood Disorders at Children’s National, and Stephen P. Hunger, ...
(Date:10/12/2017)... ... ... Health Literacy Innovations (HLI), creator of the Health Literacy ... Patient Education Network (CPEN), an independent professional organization that shares best practices in ... , As CPEN’s strategic partner, HLI will help support CPEN members by sharing ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... Sept. 27, 2017  DarioHealth Corp. (NASDAQ: DRIO), a leading global digital ... its MyDario product is expected to appear on The Dr. Oz Show ... Oz Show airs in your area: http://www.doctoroz.com/page/where-watch-dr-oz-show ... The nine-time Emmy award-winning, The Dr. Oz Show kicked off ... The segment features ...
(Date:9/25/2017)... 25, 2017  EpiVax, Inc., a leader in ... immune-engineering today announced the launch of EpiVax Oncology ... personalized therapeutic cancer vaccines. EpiVax has provided $500,000 ... to enabling technologies to the new precision immunotherapy ... EpiVax Oncology as Chief Executive Officer. Gad brings ...
(Date:9/22/2017)... Sept. 22, 2017  As the latest Obamacare repeal ... Bill Cassidy (R-LA) and Lindsey Graham ... the medical device industry is in an odd place. ... the 2.3% excise tax on medical device sales passed ... want covered patients, increased visits and hospital customers with ...
Breaking Medicine Technology: